Deep­en­ing US foot­print, As­traZeneca-part­nered French biotech In­nate shoots for $100M IPO

Fresh off of a 20th birth­day cel­e­bra­tion, French biotech In­nate Phar­ma filed for a US IPO worth up to $100 mil­lion. They de­tailed in their fil­ings a strat­e­gy to roll cash in­to pre­clin­i­cal work, ad­vanc­ing the tri­als for two drugs tar­get­ing blood can­cer and sol­id tu­mors and fur­ther test­ing the check­point in­hibitor mon­al­izum­ab, while al­so build­ing a com­mer­cial in­fra­struc­ture to mar­ket and cap­i­tal­ize on their trade­mark leukemia drug Lu­mox­i­ti.

Jen­nifer But­ler

The im­muno-on­col­o­gy biotech ac­quired its first big drug last year as it li­censed Lu­mox­i­ti from As­traZeneca. It’s the first FDA-ap­proved drug for hairy cell leukemia in 20 years. But, as they write in their F-1, al­though the com­pa­ny will be ful­ly re­spon­si­ble for mar­ket­ing the drug by 2020, they “cur­rent­ly have no sales, mar­ket­ing or com­mer­cial prod­uct dis­tri­b­u­tion or­ga­ni­za­tion and have no ex­pe­ri­ence in mar­ket­ing or man­ag­ing the man­u­fac­tur­ing of prod­ucts.”

Long­time As­traZeneca ex­ec Jen­nifer But­ler is now the head of In­nate’s US op­er­a­tions.

The com­pa­ny brought in €93 mil­lion last year (around $100 mil­lion), and €59 mil­lion in the first half of 2019 (about $65 mil­lion). They have re­ceived $550 mil­lion over the last 10 years in up­front pay­ments, mile­stone pay­ments and eq­ui­ty in­vest­ments through part­ner­ships with As­traZeneca and Sanofi and oth­ers, and they es­ti­mate they’re el­i­gi­ble for up to $5.5 bil­lion in var­i­ous pay­ments from such col­lab­o­ra­tions.

The three largest stock­hold­ers are No­vo Nordisk, Med­Im­mune (which is owned by As­traZeneca) and Bpifrance Par­tic­i­pa­tions, with co-founder Hervé Brail­ly hold­ing a 2.1% slice. No­vo ac­quired its 13.9% stake in ex­change for a new im­muno-on­col­o­gy tar­get af­ter a vaunt­ed In­nate leukemia ther­a­py flunked a Phase II tri­al. The biotech is cur­rent­ly list­ed on Eu­ronext Paris.

As of June 30, they had $220 mil­lion in cash, cash equiv­a­lents, short term in­vest­ments and non-cur­rent fi­nan­cial as­sets.

The com­pa­ny is work­ing on three class­es of prod­ucts: broad-spec­trum im­mune check­point in­hibitors, tu­mor anti­gen tar­get­ing, and sup­pres­sive fac­tors of the TME.

They are cur­rent­ly test­ing mon­al­izum­ab, their lead drug, in col­lab­o­ra­tion with As­traZeneca for sol­id tu­mors, in­clud­ing SC­CHN (head and neck) and CRC (col­orec­tal). They part­nered out that drug as part of the same deal that li­censed Lu­mox­i­ti to them, with As­traZeneca ex­er­cis­ing its $100 mil­lion for an op­tion on the drug, with an­oth­er $100 mil­lion pay­out at the first Phase III de­vel­op­ment and $825 mil­lion in po­ten­tial mile­stone mon­ey.

Pre­lim­i­nary da­ta from the lat­est 40-per­son ex­pan­sion to a Phase II tri­al showed a 27.5% re­sponse rate and one com­plete re­sponse. Fol­low-up da­ta are com­ing with­in the year.

As­traZeneca al­so agreed to fun­nel $20 mil­lion in­to four pre­clin­i­cal pro­grams, each po­ten­tial­ly worth $355 mil­lion, and pur­chased their 9.8% stake in In­nate for $72 mil­lion. In­nate paid $50 mil­lion for Lu­mox­i­ti.

This year, they al­so gained FDA fast-track sta­tus for the an­ti­body IPH4102 for treat­ment-re­sis­tant Sézary syn­drome, an ag­gres­sive form of lym­phoma, in ad­di­tion to or­phan drug des­ig­na­tions in the US and Eu­rope.

Lu­mox­i­ti was ap­proved un­der pri­or­i­ty re­view af­ter a Phase III tri­al demon­strat­ed a 75% re­sponse rate, with 30% of pa­tients re­spond­ing com­plete­ly. But there were less than 100 pa­tients and the drug was no­table among the half of all FDA-ap­proved treat­ments that were stamped based on a sin­gle tri­al in 2018.

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Sanofi

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.

Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class.  The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

Amgen has signed up to be AbbVie’s neighbor in South San Francisco as it moves into a nine-story R&D facility in the booming biotech hub.

The arrangement gives Amgen 240,000 square feet of space on the Gateway of Pacific Campus, just a few minutes drive from its current digs at Oyster Point. The new hub will open in 2022 and house the big biotech’s Bay Area employees working on cardiometabolic, inflammation and oncology research.

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Scripps and AbbVie go way back. Research conducted in the lab of Scripps scientist Richard Lerner led to the discovery of Humira. The antibody, approved by the FDA in 2002 and sold by AbbVie, went on to become the world’s bestselling treatment. In 2018, the drugmaker and the non-profit organization signed a pact focused on developing cancer treatments — and now, the scope of that partnership has broadened to encompass a range of diseases, including immunological and neurological conditions.

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

Three Samsung executives in Korea are going to jail.

The convictions came in what prosecutors had billed as “biggest crime of evidence destruction in the history of South Korea”: a case of alleged corporate intrigue that was thrown open when investigators found what was hidden beneath the floor of a Samsung BioLogics plant. Eight employees in total were found guilty of evidence tampering and the three executives were each sentenced to up to two years in prison.

Nick Plugis, Avak Kahvejian, Cristina Rondinone, Milind Kamkolkar and Chad Nusbaum. (Cellarity)

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

Cellarity started with a simple — but far from easy — idea that Avak Kahvejian and his team were floating around at Flagship Pioneering: to digitally encode a cell.

As he and his senior associate Nick Plugis dug deeper into the concept, they found that most of the models others have developed take a top-down approach, where they assemble the molecules inside cells and the connections between them from scratch. What if they opt for a top-down approach, aided by single-cell transcriptomics and machine learning, to gauge the behavior of the entire cellular network?

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

This is the second biotech buyout pact today, marking a brisk tempo of M&A deals in the lead-up to the big JP Morgan gathering in mid-January. It’s no surprise the acquisitions are both for cancer drugs, where Sanofi will try to make its mark while Merck beefs up a stellar oncology franchise. And bolt-ons are all the rage at the major pharma players, which you could also see in Novartis’ recent $9.7 billion MedCo buyout.

ArQule — which comes out on top after their original lead drug foundered in Phase III — highlighted early data on ‘531 at EHA from a group of 6 chronic lymphocytic leukemia patients who got the 65 mg dose. Four of them experienced a partial response — a big advance for a company that failed with earlier attempts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

The biopharma R&D food chain is paying off with a plan at Sanofi to pitch regulators on a new drug for an orphan disease called cold agglutinin disease.

The pharma giant ushered out a statement Tuesday morning — after it spelled out plans to radically restructure the company, abandoning cardio and diabetes research altogether — saying that their C1s inhibitor sutimlimab had cleared the pivotal study.